Adagene Inc. (ADAG) is a Biotechnology company in the Healthcare sector, currently trading at $3.81. It has a SharesGrow Score of 40/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is ADAG = $5 (+31.2% upside).
Valuation: ADAG trades at a trailing Price-to-Earnings (P/E) of -8.5 (S&P 500 average ~25).
Financials: revenue is $103,204, -4.4%/yr average growth. Net income is $33M (loss), growing at -3.1%/yr. Net profit margin is -32386.4% (negative). Gross margin is -797.5% (-897.5 pp trend).
Balance sheet: total debt is $18M against $51M equity (Debt-to-Equity (D/E) ratio 0.37, conservative). Current ratio is 2.3 (strong liquidity). Debt-to-assets is 20.7%. Total assets: $89M.
Analyst outlook: 5 / 5 analysts rate ADAG as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 90/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 0/100 (Fail), Future 100/100 (Pass), Income 10/100 (Fail).
